Latest Headlines

Latest Headlines

Aduro slips after trial patient comes down with a dangerous infection

Aduro BioTech, developing an immunotherapy combination treatment for cancer, watched its share price dip on Tuesday after quietly disclosing that a trial patient developed a serious infection tied to the company's re-engineered bacterial treatment.

AstraZeneca begins dosing in trial of its Bind-partnered cancer candidate

Cambridge, MA's Bind Therapeutics announced that patient administration of its Accurins nanoparticles has commenced in the trial of an AstraZeneca cancer candidate. Under the terms of the 2013 partnership with the Big Pharma, Bind earns a milestone payment of $4 million.

Harvard's Wyss Institute successfully tests vibration-based infant apnea prevention device

Apnea, or a prolonged pause in breathing, is quite common among premature and low-birth-weight infants and can be life-threatening. A trial at the Beth Israel Deaconess Medical Center in 36 infants with apnea of a new mattress vibration device cut the number of apnea events in half. It also improved the infant's oxygenation levels and incidents of a too-slow heart rate.

Scientists roll out innovative health-tracking device for guide dogs

Animal health companies have been rolling out wearable devices that allow owners to monitor their dog's well-being. Now researchers are developing a device that lets people who are blind keep tabs on their guide dog's health.

JAMA: Gilead, AbbVie hep C meds cost-effective even in early stages of liver disease

Payers have complained loudly about the cost of next-gen hep C meds from Gilead and AbbVie, arguing that the drugs should be reserved for the sickest patients. But now insurers are facing some evidence to the contrary, as a new study shows that new hep C meds are cost-effective when taken in early stages of the disease.

Pills loaded with mucoadhesive patches could make oral insulin a reality

Pills and patches are two drug delivery methods many patients would prefer to needles, especially when it comes to the number of injections a diabetic needs throughout the day. And now, researchers at UC Santa Barbara have combined the two to deliver insulin effectively across the intestinal wall into the blood, which could help overcome the difficulties in developing oral insulin.

ProQR tanks after slow enrollment pushes back readout from cystic fibrosis trial

ProQR Therapeutics has pushed back the date on which it expects to deliver data from its cystic fibrosis clinical trials. The delay means it may be late 2016 before ProQR presents data on its challenger to Vertex Pharmaceuticals' grip on the cystic fibrosis market.

Genmab's lymphoma project flops in Phase III with Novartis holding the bag

Genmab's plans to develop ofatumumab for lymphoma came to a halt as the company pulled the plug early on a Phase III trial that was unlikely to meet its goals, souring an investment from partner Novartis.

MIT researchers develop ingestible real-time vital sign monitor

Massachusetts Institute of Technology researchers have published an animal proof-of-concept study of their ingestible vital sign monitor that tracks heart and respiratory rates in real time.

GlaxoSmithKline inks a back-loaded $100M deal with Idera for renal R&D

GlaxoSmithKline is taking a gamble on Idera Pharmaceuticals' antisense drug technology, promising up to $100 million in a collaboration focused on renal disease.